Evidence map›Paper›PMID 33299142›Full record

ArticleLeukemia2021

SARS-CoV-2 antibody responses in patients with acute leukaemia.

J O'Nions, L Muir, J Zheng, C Rees-Spear, A Rosa, C Roustan, C Earl, P Cherepanov, R Gupta, A Khwaja and 2 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. TIGITFrontiers in immunology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

J O'NionsDepartment of Haematology, University College London NHS Foundation Trust, London, UK. jenny.onions@nhs.net.ORCID http://orcid.org/0000-0002-8917-4546
L MuirDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-7834-6066
J ZhengDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
C Rees-SpearDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-7300-2432
A RosaThe Francis Crick Institute, London, UK.
C RoustanThe Francis Crick Institute, London, UK.
C EarlThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-9091-9955
P CherepanovThe Francis Crick Institute, London, UK.
R GuptaDepartment of Haematology, University College London NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-9573-0505
A KhwajaDepartment of Haematology, University College London NHS Foundation Trust, London, UK.
C JollyDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-4603-2281
L E McCoyDivision of Infection and Immunity, University College London, London, UK. l.mccoy@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9503-7946

Funding

Medical Research Council MR/R008698/1Wellcome TrustWellcome Trust 108079/Z/15/Z
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Leukemia, Lymphocytic, Chronic, B-CellAntibody FormationHumansImmunoglobulin GSARS-CoV-2Immunoglobulin G

Identifiers

PMID33299142
PMCPMC7724438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.